Aspiro Therapeutics Establishes Advisory Board to Support Development of Lead Therapy

Tucson, Arizona / June 11, 2025 — Aspiro Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of groundbreaking, disease-modifying therapies for obstructive lung diseases, today announced the strategic addition of two new advisors: Matt Britz and Dr. Anne Dixon. Their combined leadership in respiratory science, clinical development, and biotech company building will significantly support Aspiro’s continued growth as it advances its CC16-derived therapeutic candidate, aiming to revolutionize treatment for conditions like asthma and chronic obstructive pulmonary disease (COPD).

Matt Britz is a seasoned biotech executive with broad experience across drug development, from discovery to commercialization. He has led teams across business development, manufacturing, clinical operations, regulatory affairs, and program management. Britz currently serves as CEO of Saros Therapeutics. Previously, he was CEO of AffyImmune Therapeutics, where he advanced novel CAR T therapies for solid tumors and built a focused pipeline. He has also held senior roles at Minerva Biotechnologies, Merck, Pfizer, Equinox Group, Health Advances, and Envoy Therapeutics, where he helped lead the company’s acquisition by Takeda.

Dr. Anne Dixon is a nationally recognized pulmonary clinician and researcher.  She serves as Chair of Medicine at the University of Vermont Health Network and is a Professor of Medicine at the Larner College of Medicine. Her research focuses on the impact of obesity on lung health, asthma pathophysiology, and chronic airway inflammation. Dr. Dixon’s clinical and scientific expertise will be instrumental in guiding Aspiro’s translational and clinical strategy as the company works to address the underlying mechanisms of these pervasive respiratory conditions.

“We’re honored to welcome Matt and Anne to the Aspiro team,” said James Lovgren, CEO and Co-Founder of Aspiro Therapeutics. “Their unparalleled insights into respiratory science and biotech leadership will be critical as we advance toward the clinic and continue building a company focused on long-term impact in respiratory health, ultimately transforming patient outcomes.”

Aspiro’s approach leverages cutting-edge research in CC16-inspired small peptidomimetics, a natural lung protein vital for healthy breathing, to target the underlying progression of obstructive lung diseases. By addressing disease mechanisms rather than symptoms, Aspiro aims to deliver safer, more effective treatment options for millions of patients worldwide.